Quest Diagnostics Q3 diluted EPS jumps 29% to $2.78; Q3 net revenues rise 10% to $3.1 billion

• Quest Diagnostics’ third-quarter 2026 reported diluted EPS jumped 29% year over year to $2.78.
• Net revenues rose 10% to $3.1 billion, supported by strong organic growth.
• U.S. iPhone and iPad users will be able to purchase tailored laboratory testing through Apple Health later this year.
• Raised full-year 2026 net revenues guidance to $12.07 billion–$12.11 billion and reported diluted EPS outlook to $10.21–$10.31.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quest Diagnostics Incorporated published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610220646PR_NEWS_USPR_____NY77838) on October 22, 2026, and is solely responsible for the information contained therein.